All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the MPN Advocates Network.
Join our
Treating classical Hodgkin lymphoma: Spotlight on targeted therapies
with Gilles Salles, Paul Bröckelmann, and Ann S. LaCasce
Saturday, November 2, 2024
8:50-9:50 CET
This independent educational activity is sponsored by Takeda. All content is developed independently by the faculty. Funders are allowed no direct influence on the content of this activity.
The MPN Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the MPN Hub cannot guarantee the accuracy of translated content. The MPN Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The MPN Hub is an independent medical education platform, sponsored by AOP Health and GSK, and supported through an educational grant from Bristol Myers Squibb. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
During the course of disease and subsequent treatment many patients with myeloproliferative neoplasms (MPN) report impacts on their quality of life (QoL). Previous studies have identified these impacts; however, there has been no comprehensive investigation in specific areas of patients’ life. Here, we summarize results from a survey investigating the physical, psychological, and social impacts of MPN by Eppingbroek et al.1 published in Psycho-oncology.
Patients with MPN were assessed for:
Figure 1. Hierarchical MPN patient QoL assessment model*
*Adapted from Eppingbroek AAM, et al.1
†Functional scales.
‡Symptom scales.
Table 1. EORTC QLQ-C30 assessment scores for MPN patients*
Category |
QoL impact |
EORTC QLQ-C30 score |
---|---|---|
Physical |
Fatigue |
44.3 |
|
Insomnia |
36.0 |
Psychological |
Cognitive function |
77.1 |
|
Emotional function |
66.6 |
|
Concentration |
74.7 |
Social |
Social and role function |
70.9 |
EORTC QLQ-C30, European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire; MPN, myeloproliferative neoplasms. |
Key learnings |
---|
|
Your opinion matters
Subscribe to get the best content related to MPN delivered to your inbox